Jade Biosciences, Inc. (JBIO)
JBIO moved a median of +0.19% 30 minutes after news, and -0.74% by the close. How JBIO actually reacts to news — the realized, point-in-time move the market made, measured across 124 labeled events over the last three years with zero look-ahead.
JBIO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 47% | 120 |
| 30-min | +0.19% | 52% | 124 |
| 60-min | -0.04% | 50% | 124 |
| to close | -0.74% | 38% | 120 |
| Middle 50% of JBIO reactions | -1.71% to +2.03% |
|---|---|
| Median reaction (30-min) | +0.19% |
| Measured reactions | 124 |
Half of all Jade Biosciences, Inc. news events land between -1.71% and +2.03% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How JBIO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 13 | -0.20% | 39% | -0.14% |
| Coverage initiations | 16 | +0.12% | 50% | -3.88% |
| Rating reiterations | 27 | -0.10% | 44% | -1.61% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how JBIO ranks against every other measured name →
That’s how JBIO usually reacts — get an email when it moves on news →Email me when JBIO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to JBIO's baseline. Nothing else.
Recent JBIO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Jade Biosciences, Inc. For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | -1.39% | -2.63% | |
| Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-ß Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026 | Press release | GlobeNewswire | -1.39% | -2.63% | |
| Jade Biosciences to Participate in Upcoming Conferences | Press release | GlobeNewswire | +1.10% | -1.41% | |
| Form 10-Q Jade Biosciences, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.97% | — | |
| Form 8-K Jade Biosciences, Inc. For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | +3.97% | — | |
| Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +3.97% | — | |
| Form 8-K Jade Biosciences, Inc. For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | -2.38% | -2.36% | |
| Form 8-K Jade Biosciences, Inc. For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +1.70% | +0.92% | |
| Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors | Press release | GlobeNewswire | +1.70% | +0.92% | |
| Form 8-K Jade Biosciences, Inc. For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | -0.19% | -3.40% | |
| Form DEFA14A Jade Biosciences, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -2.42% | -12.60% | |
| Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | Press release | GlobeNewswire | -2.42% | -12.60% | |
| Form 8-K Jade Biosciences, Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +1.26% | -3.31% | |
| Jade Biosciences Announces Pricing of Public Offering of Common Stock | Press release | GlobeNewswire | -6.32% | -0.84% | |
| Jade Biosciences Announces Proposed Underwritten Public Offering | Press release | GlobeNewswire | -6.32% | -0.84% | |
| Form 8-K Jade Biosciences, Inc. For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | -5.25% | -8.38% | |
| Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy | Press release | GlobeNewswire | -5.25% | -8.38% | |
| Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy | Press release | GlobeNewswire | -5.25% | -8.38% | |
| Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody | Press release | GlobeNewswire | -4.07% | -1.74% | |
| Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy | Press release | GlobeNewswire | +5.85% | +0.74% | |
| Form EFFECT Jade Biosciences, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +1.03% | -5.78% | |
| Form 10-Q Jade Biosciences, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +7.22% | +8.35% | |
| Form 8-K Jade Biosciences, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +7.22% | +8.35% | |
| Form S-3 Jade Biosciences, Inc. | SEC filing · Form S-3 | SEC EDGAR | +7.22% | +8.35% | |
| Form S-8 Jade Biosciences, Inc. | SEC filing · Form S-8 | SEC EDGAR | +7.22% | +8.35% | |
| Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +7.22% | +8.35% | |
| Form ARS Jade Biosciences, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -2.02% | -15.00% | |
| Form DEF 14A Jade Biosciences, Inc. For: Jun 09 | SEC filing · Form DEF | SEC EDGAR | -2.02% | -15.00% | |
| Form DEFA14A Jade Biosciences, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -2.02% | -15.00% | |
| Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.43% | -0.20% | |
| Form 8-K Jade Biosciences, Inc. For: Apr 18 | SEC filing · Form 8-K | SEC EDGAR | +5.48% | +10.30% | |
| Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer | Press release | GlobeNewswire | +5.48% | +10.30% | |
| Form PRE 14A Jade Biosciences, Inc. For: Jun 09 | SEC filing · Form PRE | SEC EDGAR | -0.35% | +4.40% | |
| Form 8-K Jade Biosciences, Inc. For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.39% | |
| Form 10-K Jade Biosciences, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.24% | -0.07% | |
| Form 8-K Jade Biosciences, Inc. For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | +1.71% | +4.54% | |
| Form POS EX Jade Biosciences, Inc. | SEC filing · Form POS | SEC EDGAR | +0.24% | -0.07% | |
| Form S-8 Jade Biosciences, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.24% | -0.07% | |
| Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +1.71% | +4.54% | |
| Jade Biosciences to Participate in Upcoming Conferences | Press release | GlobeNewswire | +0.54% | +2.03% | |
| Form 8-K Jade Biosciences, Inc. For: Jan 05 | SEC filing · Form 8-K | SEC EDGAR | +1.60% | -4.51% | |
| Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +1.60% | -4.51% | |
| Form EFFECT Jade Biosciences, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.61% | -1.09% | |
| Form EFFECT Jade Biosciences, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -0.65% | |
| Form S-1 Jade Biosciences, Inc. | SEC filing · Form S-1 | SEC EDGAR | +0.81% | -1.45% | |
| Form 8-K Jade Biosciences, Inc. For: Dec 13 | SEC filing · Form 8-K | SEC EDGAR | -0.36% | -0.39% | |
| Jade Biosciences Announces $45 Million Private Placement | Press release | GlobeNewswire | -0.36% | -0.39% | |
| Form 10-Q Jade Biosciences, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.51% | +11.46% | |
| Form 8-K Jade Biosciences, Inc. For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | +1.51% | +11.46% | |
| Form S-1 Jade Biosciences, Inc. | SEC filing · Form S-1 | SEC EDGAR | +4.54% | +14.46% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the JBIO section they belong to.
Where else JBIO is measured.
JBIO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Jade Biosciences, Inc.'s median reaction calculated?
Every labeled JBIO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 124 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of JBIO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does JBIO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.